No survival benefit found after extended treatment with docetaxel for patients with castration-resistant prostate cancer.
Tanaka M, Kimura T, Iwamura Y, Enei Y, Iwamoto Y, Imai Y, Inaba Y, Matsukawa A, Onuma H, Ito K, Mori K, Sasaki H, Miki J, Furuta A, Miki K, Egawa S.
Tanaka M, et al. Among authors: mori k.
Prostate. 2019 Oct;79(14):1604-1610. doi: 10.1002/pros.23884. Epub 2019 Aug 2.
Prostate. 2019.
PMID: 31376184